Myelofibrosis
MF · Oncology · 4 drugs · 4 indications
Myeloproliferative neoplasm with bone marrow fibrosis.
Competitive Landscape (4 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Pelabresib | NVS | BET inhibitor | Small molecule | Oral | PHASE3 |
| Vonjo | SOBI | JAK2/IRAK1 inhibitor | Small molecule | PO | APPROVED |
| Jakafi | — | JAK1/JAK2 inhibitor | Small molecule | PO | APPROVED |
| Ojjaara | — | JAK1/JAK2 inhibitor | Small molecule | PO | APPROVED |
Indications (4)
Myelofibrosis (intermediate/high risk)
Myelofibrosis with anemia
Myelofibrosis with severe thrombocytopenia
Myelofibrosis (JAK-inhibitor naive)
Upcoming Catalysts
Pelabresib - Myelofibrosis - EU Filing/ApprovalREGULATORY
NVS2026
Pelabresib - Myelofibrosis - Ph3 - Start (MANIFEST-3)CLINICAL
NVS2026
Vonjo - MF (severe thrombocytopenia) - Ph3 - Confirmatory (PACIFICA)CLINICAL
SOBI2026-2027
Data from Supabase · Updated 2026-03-24